Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China. This is a post-marketing, interventional, multi-center, double-arm, prospective, open-label, randomized controlled study in elderly patients with MDS/AML/CMML in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given azacytidine + HAG regimen or azacytidine under the conditions of informed consent and frequent monitoring according to the clinical guideline.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Second People's Hospital
• Treatments: Azacitidine; Cytarabine

Criteria

Inclusion Criteria:

• Age ≥ 60;

• Patients with newly diagnoised diseases including MDS/AML/CMML;

• The ECOG behavior status score is less than 3 points;

• Agree to sign informed consent

Exclusion Criteria:

• Patients with a history of sever heart disease;

• Patients with severe organ dysfunction;

• Patients with other malignancies

• Patients who are allergic to the treatment of drug ingredients